Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced positive data from the company's Phase 1b clinical trial of VK0214,

X-ALD is a rare and often fatal metabolic disorder characterized by a breakdown in the protective barriers surrounding brain and nerve cells. The Phase 1b study was designed to evaluate the safety and tolerability of VK0214 in adult male patients with the adrenomyeloneuropathy (AMN) form of X-ALD,

Viking Therapeutics Inc.’s stock rose 1.4% in premarket trade Wednesday, after the biotech reported positive data from an early-stage trial of a treatme